RxDoctor Payments Data

Valerie Rumple

Psychiatric/Mental Health · Fort Wayne, INNPI 1174706691

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,789 of the $7,948 with a category attached, or 85.4%. It is spread thinly across 24 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,948in general payments, 2019–2025

Across 379 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$1K
  • Brainsway USA Inc$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$633
  • Sunovion Pharmaceuticals Inc.$568
  • Lundbeck LLC$544
  • plus $3K from 18 others

What the payments were for

  • Travel & lodging$1,02913%
  • Food & beverage$6,78985%
  • Education$1302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,948 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$19,667
Medicare patients
95
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate232$746,362
AustedoDeutetrabenazine71$480,144
Abilify MaintenaAripiprazole101$290,914
VraylarCariprazine Hcl113$185,187
Invega TrinzaPaliperidone Palmitate22$163,494
RexultiBrexpiprazole108$143,621
IngrezzaValbenazine Tosylate17$136,960
Abilify AsimtufiiAripiprazole17$97,379
TrintellixVortioxetine Hydrobromide120$77,001
SpravatoEsketamine Hcl32$43,222
CaplytaLumateperone Tosylate22$38,882
LybalviOlanzapine/Samidorphan Malate26$37,449
QuviviqDaridorexant Hcl66$37,361
Austedo XrDeutetrabenazine11$36,727
FanaptIloperidone12$25,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato, Risperdal Consta$174$968,149310 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti, Abilify Asimtufii$1,387$531,913226 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$444$516,87182 claims
AbbVieVraylar$1,058$185,187113 claims
Neurocrine Biosciences, Inc.Ingrezza$181$136,96017 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$225$77,001120 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$633$38,88222 claims
Alkermes, Inc.Lybalvi$446$37,44926 claims
Idorsia Pharmaceuticals US IncQuviviq$18$37,36166 claims
Vanda Pharmaceuticals Inc.Fanapt$61$25,57412 claims
MerckBelsomra$18$19,72535 claims
Axsome Therapeutics, Inc.Auvelity$509$10,99011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →